Published in Med J Aust on August 06, 2012
Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASP-13). Comment. Med J Aust (2013) 1.08
Clinical predictors of acute kidney injury following snake bite envenomation. N Am J Med Sci (2013) 0.99
Neurotoxicity in snakebite--the limits of our knowledge. PLoS Negl Trop Dis (2013) 0.95
Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming. Toxins (Basel) (2017) 0.75
Clinical and Pharmacological Investigation of Myotoxicity in Sri Lankan Russell's Viper (Daboia russelii) Envenoming. PLoS Negl Trop Dis (2016) 0.75
Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASP-13). Med J Aust (2013) 0.75
The specificities of protein kinase inhibitors: an update. Biochem J (2003) 7.76
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol (2006) 6.64
Feeding aquaculture in an era of finite resources. Proc Natl Acad Sci U S A (2009) 4.11
Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med (2006) 3.00
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep (2004) 2.31
Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab (2010) 1.79
The selectivity of inhibitors of protein kinase CK2: an update. Biochem J (2008) 1.45
Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem (2007) 1.37
Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem (2004) 1.26
Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J (2003) 1.22
Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry (2004) 1.16
Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol (2009) 1.06
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J (2003) 1.04
Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure (2004) 1.04
Comparison of PIRO, SOFA, and MEDS scores for predicting mortality in emergency department patients with severe sepsis and septic shock. Acad Emerg Med (2014) 1.03
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J (2009) 1.02
A pharmacological approach to first aid treatment for snakebite. Nat Med (2011) 1.00
Pleurodesis for primary spontaneous pneumothorax. Lancet (2013) 0.96
Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational study. PLoS One (2013) 0.96
FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. Med J Aust (2011) 0.95
Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom. Toxicon (2010) 0.93
The in vitro toxicity of venoms from South Asian hump-nosed pit vipers (Viperidae: Hypnale). J Venom Res (2011) 0.92
Characterisation of major peptides in 'jack jumper' ant venom by mass spectrometry. Toxicon (2004) 0.90
Cross-neutralisation of the neurotoxic effects of Egyptian cobra venom with commercial tiger snake antivenom. Basic Clin Pharmacol Toxicol (2012) 0.86
Cross-neutralisation of Australian brown snake, taipan and death adder venoms by monovalent antibodies. Vaccine (2009) 0.86
Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays. Neuropharmacology (2011) 0.85
Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon (2005) 0.84
Outreach surgical consulting services in North East Victoria. Aust J Rural Health (2013) 0.83
Clinical effects of red-bellied black snake (Pseudechis porphyriacus) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASP-11). Med J Aust (2010) 0.83
Scorpion envenomation. N Engl J Med (2014) 0.83
Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14). PLoS One (2012) 0.83
Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. PLoS Negl Trop Dis (2013) 0.83
Death adder envenoming causes neurotoxicity not reversed by antivenom--Australian Snakebite Project (ASP-16). PLoS Negl Trop Dis (2012) 0.82
Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming? Med J Aust (2010) 0.81
Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon (2006) 0.81
Clinical and epidemiological profile of patients with severe H1N1/09 pandemic influenza in Australia and New Zealand: an observational cohort study. BMJ Open (2011) 0.81
A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br J Clin Pharmacol (2007) 0.81
Envenoming by the rough-scaled snake (Tropidechis carinatus): a series of confirmed cases. Med J Aust (2009) 0.81
Mediators released during human anaphylaxis. Curr Allergy Asthma Rep (2012) 0.81
Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: detecting venom, antivenom and venom-antivenom complexes. Toxicon (2006) 0.80
Human anti-snake venom IgG antibodies in a previously bitten snake-handler, but no protection against local envenoming. Toxicon (2009) 0.79
Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. J Pharm Biomed Anal (2007) 0.78
Critical illness in the emergency department: lessons learnt from the first 12 months of enrolments in the Critical Illness and Shock Study. Emerg Med Australas (2011) 0.78
Using time-resolved fluorescence to measure serum venom-specific IgE and IgG. PLoS One (2011) 0.78
Angiotensin-converting enzyme insertion/deletion polymorphism and severe hypoglycemia complicating type 2 diabetes: the Fremantle Diabetes Study. J Clin Endocrinol Metab (2011) 0.77
Serial multiple biomarkers in the assessment of suspected acute coronary syndrome: multiple infarct markers in chest pain (MIMIC) study. Emerg Med J (2012) 0.77
Parenteral antihistamines cause hypotension in anaphylaxis. Emerg Med Australas (2013) 0.76
Modified TIMI risk score cannot be used to identify low-risk chest pain in the emergency department: a multicentre validation study. Emerg Med J (2013) 0.76
Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy. J Pharm Biomed Anal (2010) 0.76
Anaphylaxis--recognition and management. Aust Fam Physician (2012) 0.76
Immediate-type hypersensitivity drug reactions. Br J Clin Pharmacol (2014) 0.76
Myth of tension spontaneous pneumothorax. Emerg Med Australas (2012) 0.75
Cardiac arrhythmia or movement artefact? Emerg Med Australas (2009) 0.75
Parallel infusion of hydrocortisone with/without chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med J Aust (2004) 0.75
Efficacy of ant venom immunotherapy and whole body extracts. J Allergy Clin Immunol (2005) 0.75
Antihistamines for anaphylaxis? Primary outcome measures. BMJ (2009) 0.75
Anaphylaxis to bull dog ant and jumper ant stings around Perth, Western Australia. Emerg Med Australas (2006) 0.75
Use of a risk nomogram to predict emergency department reattendance in older people after discharge: a validation study. Intern Emerg Med (2015) 0.75
Management of anaphylaxis in an austere or operational environment. J Spec Oper Med (2014) 0.75
Changes in differential gene expression during a fatal stroke. J Clin Neurosci (2016) 0.75
A randomized-controlled trial of a patient-centred intervention in high-risk discharged older patients. Eur J Emerg Med (2016) 0.75
Clinically applicable laboratory end-points for treating snakebite coagulopathy. Pathology (2006) 0.75
High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom. Med J Aust (2006) 0.75